| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.078 | 0.06 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.085 | 0.07 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.07 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.07 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.069 | 0.07 |
| mRNA | JQ-1:MK-0752 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.063 | 0.07 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.07 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.07 | 0.07 |